Published in J Clin Oncol on July 01, 1993
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | NCT01755195
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res (2011) 1.25
Pediatric soft tissue sarcomas. Surg Clin North Am (2008) 1.21
Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. Ann Surg (2000) 1.20
Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma (2000) 1.12
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res (2008) 1.12
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol (2013) 1.11
Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol (2013) 1.08
Radiation-induced sarcoma of the breast: a systematic review. Oncologist (2012) 1.05
Management of resectable gastrointestinal stromal tumor. Hematol Oncol Clin North Am (2009) 1.03
Primary malignant fibrous histiocytoma of the lung: a case report. Case Rep Med (2010) 1.03
Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin. Sarcoma (2009) 1.01
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs (2015) 0.95
Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer (2011) 0.95
Metastatic pleomorphic sarcoma to left atrium. Rare Tumors (2009) 0.95
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer (1998) 0.93
Primary intra-abdominal malignant fibrous histiocytoma presenting as pyrexia of unknown origin--report of a case with review of literature. Int Semin Surg Oncol (2006) 0.92
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs (2007) 0.89
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Invest New Drugs (2006) 0.89
Current treatment of soft tissue sarcoma. Proc (Bayl Univ Med Cent) (2008) 0.88
Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Core Evid (2010) 0.87
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) (2013) 0.87
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma (2013) 0.86
Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther (2009) 0.86
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs (2000) 0.86
Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. Surg Today (2011) 0.85
Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag (2008) 0.84
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs (2009) 0.84
Advanced epithelioid malignant peripheral nerve sheath tumor showing complete response to combined surgery and chemotherapy: a case report. Case Rep Oncol Med (2011) 0.84
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs (2006) 0.84
Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline. Curr Oncol (2007) 0.82
Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. Sarcoma (2008) 0.82
Malignant fibrous histiocytoma arising from the omentum presenting as hemoperitoneum. Gut Liver (2010) 0.81
Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. Int Semin Surg Oncol (2005) 0.80
A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. Sarcoma (2006) 0.80
Outcome analysis in patients with uterine sarcoma. Radiat Oncol J (2015) 0.80
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer (2004) 0.80
Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Mol Oncol (2014) 0.80
Liposarcoma of the thyroid. Sarcoma (2004) 0.79
Management of advanced adult soft tissue sarcoma. Sarcoma (2003) 0.79
High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre. Sarcoma (2004) 0.78
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer (2006) 0.77
Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine. Angew Chem Int Ed Engl (2017) 0.77
Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth. Clin Orthop Relat Res (2008) 0.77
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. Invest New Drugs (2009) 0.76
Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group. Sarcoma (2003) 0.76
Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors. Sarcoma (1999) 0.76
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs (2013) 0.75
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Outcomes and toxicity of radiotherapy for refractory bone and soft tissue sarcomas. Mol Clin Oncol (2015) 0.75
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol (2016) 0.75
Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res (2016) 0.75
Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas. Clin Exp Metastasis (2007) 0.75
Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma. Sarcoma (1999) 0.75
Targeted therapy for soft tissue sarcomas in adolescents and young adults. Adolesc Health Med Ther (2017) 0.75
First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clin Sarcoma Res (2015) 0.75
Monophasic synovial sarcoma presenting as mitral valve obstruction. Tex Heart Inst J (2010) 0.75
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biol Open (2016) 0.75
A trimodality approach in the management of metastatic low-grade epithelioid hemangioendothelioma of the bone. BMJ Case Rep (2015) 0.75
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol (2017) 0.75
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs (2016) 0.75
Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol (2017) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature (1985) 4.02
Generalized additive distributed lag models: quantifying mortality displacement. Biostatistics (2000) 3.52
Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab (2001) 3.43
Tutorial in biostatistics methods for interval-censored data. Stat Med (1998) 3.29
The teratogenicity of anticonvulsant drugs. N Engl J Med (2001) 3.09
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Extrapulmonary small cell carcinoma. Cancer (1997) 2.61
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res (1999) 2.50
Leiomyomatous neoplasms of the lung: a clinical, histologic, and immunohistochemical study. Mod Pathol (1989) 2.32
Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med (1995) 2.15
Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum Pathol (1972) 2.00
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Malignant "Triton" tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer (1985) 1.84
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med (1988) 1.82
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int (2013) 1.79
Complications of cancer immunotherapy with levamisole. Lancet (1977) 1.76
Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med (1978) 1.74
Pressure-dependent metallic and superconducting phases in a germanium artificial metal. Phys Rev Lett (2009) 1.73
HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Cloning of an intracellular Poly[D(-)-3-Hydroxybutyrate] depolymerase gene from Ralstonia eutropha H16 and characterization of the gene product. J Bacteriol (2001) 1.70
Orbit, a novel microtubule-associated protein essential for mitosis in Drosophila melanogaster. J Cell Biol (2000) 1.66
Functionalized pentacene: improved electronic properties from control of solid-state order. J Am Chem Soc (2001) 1.59
Retinoids in cancer therapy. J Clin Oncol (1992) 1.59
The reflex sympathetic dystrophy syndrome (RSDS). III. Scintigraphic studies, further evidence for the therapeutic efficacy of systemic corticosteroids, and proposed diagnostic criteria. Am J Med (1981) 1.57
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol (1988) 1.56
Nosocomial sepsis associated with interleukin-2. Ann Intern Med (1990) 1.56
Gallbladder and biliary tract candidiasis: nine cases and review. Rev Infect Dis (1990) 1.56
Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs (1991) 1.53
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol (1996) 1.52
The area and volume of single human erythrocytes during gradual osmotic swelling to hemolysis. Can J Physiol Pharmacol (1970) 1.50
Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49
Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res (1996) 1.45
The long-term effect of menopause on postmenopausal bone loss in Japanese women: results from a prospective study. J Bone Miner Res (1998) 1.45
Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid). Analysis of thirty cases followed up for ten or more years. Cancer (1967) 1.45
Primary cutaneous osteosarcoma. Am J Dermatopathol (1995) 1.43
Anticancer drug discovery and development throughout the world. J Clin Oncol (2002) 1.42
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int (2008) 1.42
Levamisole as adjuvant therapy for melanoma: quo vadis? J Clin Oncol (1991) 1.40
Letter: pre-operative anti-TNF-α and post-operative complications in ulcerative colitis. Aliment Pharmacol Ther (2012) 1.39
Alveolar rhabdomyosarcoma. An analysis of 110 cases. Cancer (1969) 1.39
Bone scintigraphy in the reflex sympathetic dystrophy syndrome. Radiology (1981) 1.38
Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol (1993) 1.37
Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone (2002) 1.37
Synovial origins of Rice bodies in joint fluid. Arthritis Rheum (1980) 1.31
Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun (1999) 1.31
Cementum and dentin in hypophosphatasia. J Dent Res (2005) 1.31
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys (1998) 1.29
Diabetic mastopathy: a distinctive clinicopathologic entity. Hum Pathol (1992) 1.29
Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun (1995) 1.26
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25
MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol (2001) 1.21
Ectopic expression of DREF induces DNA synthesis, apoptosis, and unusual morphogenesis in the Drosophila eye imaginal disc: possible interaction with Polycomb and trithorax group proteins. Mol Cell Biol (2001) 1.21
Milwaukee Shoulder syndrome: eleven additional cases with involvement of the knee in seven (basic calcium phosphate crystal deposition disease). Semin Arthritis Rheum (1984) 1.21
Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int (1994) 1.20
A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg (2001) 1.19
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19
Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis. Clin Exp Immunol (1984) 1.18
Rhabdomyolysis and renal failure in hypothyroidism. Ann Intern Med (1979) 1.17
HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab Invest (1998) 1.17
Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res (1983) 1.17
Prognostic factors for survival in hepatocellular carcinoma. Cancer Res (1988) 1.16
Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest (1995) 1.15
The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol (1982) 1.15
High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am (1997) 1.15
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med (1979) 1.14
MCM2--a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer (2001) 1.14
Articular cartilage vesicles generate calcium pyrophosphate dihydrate-like crystals in vitro. Arthritis Rheum (1992) 1.14
Pigmented villonodular synovitis of a lumbar facet joint. AJNR Am J Neuroradiol (1992) 1.14
Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women. Osteoporos Int (2012) 1.13
Local EM estimation of the hazard function for interval-censored data. Biometrics (1999) 1.13
Efficiency of age-adjusted tests in animal carcinogenicity experiments. Biometrics (1985) 1.13
Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition (2001) 1.13
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer (1987) 1.12
Human restriction fragment length polymorphisms and cancer risk assessment. J Cell Biochem (1986) 1.12
When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA (1984) 1.12
Management of nausea and vomiting in the cancer patient. JAMA (1981) 1.11
Inorganic pyrophosphate metabolism in arthritis. Rheum Dis Clin North Am (1988) 1.11
Transforming growth factor beta 1 stimulates inorganic pyrophosphate elaboration by porcine cartilage. Arthritis Rheum (1991) 1.10
Letter: the impact of smoking on clinical outcomes after endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther (2013) 1.08
Inhibitory effects of elevated temperature on human cytokine production and natural killer activity. Cancer Res (1986) 1.08
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer (1990) 1.07
Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr (1982) 1.07
Release of pyrophosphate by normal mammalian articular hyaline and fibrocartilage in organ culture. Arthritis Rheum (1981) 1.06
Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. Blood (1982) 1.06
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
Sperm aneuploidy among Chinese pesticide factory workers: scoring by the FISH method. Am J Ind Med (1999) 1.04
A variable tandem repeat locus mapped to chromosome band 10q26 is amplified and rearranged in leukocyte DNAs of two cancer patients. Nucleic Acids Res (1986) 1.04